EVIO, Inc.
EVIO
Other OTC0.00
USD
- -
- -
CIK
0000715788
ISIN
US30051V1061
CUSIP
30051V106
Return %
Stock
S&P500
1Y
4,900.00
26.53
3Y
- -
76.60
5Y
-97.55
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Lori Jean Glauser
- Full Time Employees
- 18
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 2340 West Horizon Ridge Parkway Henderson NV United States of America 89052
- IPO Date
- Jan 21, 2004
- CIK
- 0000715788
- Website
- eviolabs.com
- Similar Companies
- Business
- EVIO, Inc. (OTC: EVIO) operates as a diversified holding company primarily providing analytical testing, consulting, and advisory services to the cannabis, hemp, and related agricultural and pharmaceutical industries. The company offers comprehensive laboratory testing including potency quantitation, pesticide residue analysis for over 100 agrochemicals, residual solvents detection, mycotoxin screening, microbial contamination testing for bacteria and fungi, heavy metals analysis for lead, cadmium, mercury, and arsenic, as well as moisture content and water activity assessments; it also delivers compliance consulting, product research and development, formulation support, and scientific advisory services through subsidiaries such as EVIO Labs, Greenhaus Analytical Labs, and others. Operations span multiple U.S. states including Oregon, California, Massachusetts, Florida, and Colorado, with historical presence in Canada, targeting regulated cannabis producers, processors, and distributors requiring state-mandated quality assurance. Founded in 2014 and headquartered in Henderson, Nevada, EVIO has historically maintained accredited labs across key cannabis markets but underwent significant strategic shifts in recent years, including the 2022 sale of its Portland analytical testing lab to PREE Laboratories for $850,000 to reduce over $3 million in debt, closure of its Berkeley-based C3 Labs, and a pivot away from core U.S. cannabis testing operations toward diversification into construction, mining, and pharmaceutical services. In 2022, the company completed a debt restructuring settling $596,000 of obligations for $205,000, expanded its Coast to Coast Contracting and Consulting subsidiary in Florida to include roofing and restoration services via a letter of intent with Greenhaus Analytical Labs, and formed a strategic partnership with Rare Earth Genomics Texas for hemp research and development as well as with Chroma Signet for blockchain-based product verification using NFTs. These moves reflect a broader cost-reduction strategy, withdrawal of a Regulation A offering, and focus on non-dilutive growth in ancillary sectors without new equity issuances.
EVIO Teams with Molicel to Advance Energy Storage Development
EVIO Launches Hybrid-Electric Aircraft Program with 450 Pre-Orders
EVIO, Inc. provides Shareholder Update
EVIO Inc. Provides Shareholder Update